Literature DB >> 2298417

Combination chemotherapy and radiation for stage IV breast cancer during pregnancy.

P H Willemse1, R van der Sijde, D T Sleijfer.   

Abstract

A 42-year-old woman presented with a 25-week pregnancy and stage IV breast cancer with metastases in the skeleton and liver and a T-4 primary tumor. She was treated with two cycles of doxorubicin, methotrexate, and vincristine. Spontaneous labor resulted in a normal female infant, who was successfully treated for sepsis and mild respiratory distress. The placenta showed diffuse chorioamnionitis. There was no doxorubicin demonstrated in the placenta, blood, or fetal lymphocytes 3 weeks after the last treatment. Maternal and fetal chromosomal analyses were unremarkable. The child is functioning normally 2 years after delivery. The literature on anthracycline treatment during pregnancy is reviewed. Adriamycin has been shown to cross the blood-placenta barrier, but has not led to specific fetal abnormalities when given during the second or third trimester. Experience during the first trimester is still limited.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2298417     DOI: 10.1016/0090-8258(90)90188-q

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.

Authors:  Brian L Burnette; Mark A Jentoft; Luis F Porrata; Thomas G Boyce; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2014-01-06       Impact factor: 44.544

Review 2.  Treating breast cancer during pregnancy. What can be taken safely?

Authors:  M Espié; C Cuvier
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 3.  Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy.

Authors:  Silvia Triarico; Serena Rivetti; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 4.  Investigation of 7-dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review.

Authors:  M R Boland; N P Tatonetti
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.